Nebraska is conducting the first clinical trial of possible coronavirus treatment, which is expected to eventually include 400 patients in 50 locations around the world, officials said. In this international study, halfRead More…
Innovation drives progress. Center for Drug Evaluation and Research (CDER) of FDA has been a strong supporter of innovation in the development of new drugs and biotherapy products. By understanding the mechanismRead More…
Incidence of lung cancer Lung cancer has the highest incidence of cancer in the world. According to WHO’ statistics, there are an estimated 18.1 million new cancer patients worldwide in 2018, ofRead More…
In a study published in the international journal ACS Nano, scientists from Rutgers University have developed a new nanotechnology. It may accelerate the research in the field of stem cell transplantation andRead More…
B lymphocytes can only produce a proprietary antibody against an antigen determinant, so it has the characteristics of highly specific physical and chemical properties, single biological activity, strong binding specificity with antigenRead More…
The outbreak of Ebola in 2014 in West Africa killed more than 11000 people. At the time, scientists were working on several experimental vaccines and treatments, but none of them were approvedRead More…
Melanin protects us from the sun’s destructive rays by absorbing light energy and converting it into heat. A recent study has shown that this can make it a very effective tool forRead More…
Scientists, from the German Cancer Research Center (DKFZ), have successfully reconstructed biomolecules in the form of images. The goal of the researchers is to create a mirror artificial protein synthesis system. InRead More…
Alzheimer’s disease (AD) is a neurodegenerative disease common in the elderly. The main pathological changes were diffuse atrophy of cerebral cortex, neurofibrillary tangles and the formation of a large number of senileRead More…
Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…